[Androgen therapy of incurable breast neoplasms. Controlled clinical study: nandrolone-testololactone-drostanolone].

Abstract

In 91 patients with advanced breast cancer testololactone, drostanolone, and nandrolone were compared in a controlled clinical trial. Remissions were registered after 4 weeks and after another 12 week period; during this second interval the patients received an additional treatment with cyclophosphamide. There was no difference in the effectivity between the three drugs. Remission rate was in average after 4 weeks 24% and after 16 weeks 46%.

• Authors: G Wolff, K Rieche
• Journal: Onkologie (Onkologie) Vol. 1 Issue 4 Pg. 172-4 (Aug 1978) ISSN: 0378-584X [Print] Switzerland
• Vernacular Title: Zur Androgentherapie des inkurablen Mammakarzinoms Kontrollierter klinischer Versuch: Nandrolon-Testololakton-Drostanolon.
• PMID: 362297 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Androstanols
• Androstenes
• Testosterone Congeners
• testololactone
• Testolactone
• Nandrolone
• Cyclophosphamide

Topics

• Androstanols (therapeutic use)
• Androstenes (therapeutic use)
• Breast Neoplasms (drug therapy)
• Clinical Trials as Topic
• Cyclophosphamide (therapeutic use)
• Drug Evaluation
• Female
• Humans
• Nandrolone (therapeutic use)
• Testolactone (analogs & derivatives)
• Testosterone Congeners (therapeutic use)
• Virilism (chemically induced)